ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Phio Pharmaceuticals (PHIO)
Phio Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.85▲ +0.52%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Phio Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Phio Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Phio Pharmaceuticals a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.77 and $0.93; in 9 out of 10, between $0.65 and $1.09. Estimated annual volatility is 41%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $11.4M
- 52-week high
- $2.07
- 52-week low
- $0.81
- Revenue (12 months)
- $0.0M
- Return on equity
- -113.7%
- Free cash flow (12 months)
- $-7.7M
- Beta
- 0.80
What this means
ATLAS does not publish a fair value for PHIO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks PHIO has traded between $0.81 and $2.07. Today it is 58.6% below that high and 5% above its low.
Its beta is 0.80: it tends to move less than the market.
About the company
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform.
Want to see everything about Phio Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Phio Pharmaceuticals do?
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform.
What is the chance PHIO goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, PHIO ends the month between $0.77 and $0.93.
How big is Phio Pharmaceuticals and what is its P/E ratio?
Phio Pharmaceuticals's market capitalization is $11.4M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is PHIO?
ATLAS estimates annual volatility at 41%. In a typical month, half of the outcomes end between $0.77 and $0.93.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer